Key Dates
PAR-20-292 - NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
National Cancer Institute (NCI)
The National Cancer Institute (NCI) intends to reissue the NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) Funding Opportunity Announcement (FOA), which supports preclinical and early-phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer disparities. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical). The FOA is intended to be a re-issuance of PAR-20-292.
This Notice of Intent to Publish (NOITP) is being provided to allow sufficient time for applicants to develop strong applications.
The FOA is expected to be published in August 2022 with an expected first application due date in October, 2022.
This Funding Opportunity Announcement (FOA) supports areas of cancer research relevant to the mission of the Division of Cancer Treatment and Diagnosis (DCTD), the Division of Cancer Prevention (DCP), and the Center to Reduce Cancer Health Disparities (CRCHD). These include (but are not limited to):
- preclinical and clinical studies that focus on the development and testing of anti-cancer, symptom management, and cancer prevention interventions (drugs, biologics, natural products, dietary compounds or constituents, or complementary/alternative medicine), including combinations of agents;
- diagnostic and treatment methodologies;
- validation of predictive biomarkers for clinical use;
- clinical and translational studies that seek to reduce the unequal burden of cancer in our society via research of underserved populations;
- testing (in prevention, symptom management, and/or treatment studies) of new models that closely parallel the development and progression of human cancers or the development of disease and treatment-related morbidities;
- comparative oncology studies of prevention, symptom management, and/or treatment of pet dogs with spontaneous cancers.
Non-responsive Applications: This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways, molecular mechanisms, or mechanisms of metastasis), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed.
TBD
$120 M
300
The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in a single year.
93.393, 93.394, 93.395, 93.396, 93.399
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Regional Organization
Eligible Agencies of the Federal Government
Applications are not being solicited at this time.
Please direct all inquiries to:
Morgan O'Hayre, Ph.D.
National Cancer Institute (NCI)
240-276-7482
Applications Related to Cancer Treatment/Diagnosis (Preclinical Studies):
Morgan O'Hayre, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-7482
Email: [email protected]
Applications Related to Cancer Treatment/Diagnosis (Clinical Studies):
Minkyung (Min) Song, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-6139
Email: [email protected]
Applications Related to Cancer Prevention/Symptom Management:
Marjorie Perloff, MD
National Cancer Institute (NCI)
Telephone: 240-276-7097
Email: [email protected]
Applications Related to Cancer Health Disparities:
Tiffany Wallace, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5114
Email: [email protected]
and Human Services (HHS)
